Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 2Recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 6OTHER_GOV 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2

Interventions

pembrolizumab 9Drug Therapy 9Bevacizumab 9Radiotherapy 8Carboplatin 8Oxaliplatin 7Cyclophosphamide 7Surgical Procedures, Operative 6Cisplatin 6Capecitabine 6tislelizumab 5Paclitaxel 5Fluorouracil 5Docetaxel 5Control Groups 5Nivolumab 4Immune Checkpoint Inhibitors 4Gemcitabine 4Endoscopic Mucosal Resection 4sintilimab 3fludarabine 3Trastuzumab 3Pemetrexed 3Neoadjuvant Therapy 3Leucovorin 3Laparoscopy 3Irinotecan 3Injections 3Hematologic Tests 3HMPL-013 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × Levoleucovorin × Clear all
NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Fujian Cancer Hospital

Phase 3 Recruiting
269 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Fujian Cancer Hospital

Phase 1/2 Recruiting
51 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡